Cullinan Therapeutics (CGEM) Accounts Payables (2020 - 2026)

Cullinan Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 26.23% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 26.23% decrease from a year earlier, with the FY2025 full-year figure at $841000.0, down 50.0% from the prior year.
• Accounts Payables improved to $2.5 million in Q1 2026 per CGEM's latest filing, from $841000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $6.3 million in Q1 2022 and bottomed at $841000.0 in Q4 2025.
• The 5-year median for Accounts Payables is $2.5 million (2025), against an average of $2.4 million.
• Across the five-year window, Accounts Payables sank 67.79% in 2023 and surged 122.4% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $2.7 million in 2022, then dropped by 6.28% to $2.5 million in 2023, then tumbled by 32.53% to $1.7 million in 2024, then sank by 50.0% to $841000.0 in 2025, then surged by 198.34% to $2.5 million in 2026.
• Per Business Quant, the three latest CGEM Accounts Payables figures stand at $2.5 million (Q1 2026), $841000.0 (Q4 2025), and $1.7 million (Q3 2025).